Dacogen Disease Interactions
There are 3 disease interactions with Dacogen (decitabine).
Decitabine (applies to Dacogen) liver impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
There are no data on the use of decitabine in patients with hepatic dysfunction. Decitabine should be used with caution in these patients.
Decitabine (applies to Dacogen) hematological toxicity
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Thrombocytopenia, Neutropenia
Treatment with decitabine is associated with neutropenia and thrombocytopenia. It is recommended to consider the need for early institution of growth factors and/or antimicrobial agents for the prevention or treatment of infections in patients with myelodysplastic syndromes (MDS). Complete blood and platelet counts should be performed as needed to monitor response and toxicity, but at a minimum, before each dosing cycle. After administration of the recommended dosage for the first cycle, treatment for subsequent cycles should be adjusted according to manufacturer recommendations. Myelosuppression and worsening neutropenia may occur more frequently in the first or second treatment cycles and may not necessarily indicate progression of underlying MDS. Closely monitor patients at risk for hematological toxicities.
Decitabine (applies to Dacogen) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
There are no data on the use of decitabine in patients with renal dysfunction. Decitabine should be used with caution in these patients.
Switch to professional interaction data
Dacogen drug interactions
There are 225 drug interactions with Dacogen (decitabine).
Report options
More about Dacogen (decitabine)
- Dacogen consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antimetabolites
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Reblozyl
Reblozyl is used to treat anemia in adults with beta-thalassemia or myelodysplastic syndromes ...
Vidaza
Vidaza is used to treat certain types of bone marrow cancers and blood cell disorders. Learn about ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Tibsovo
Tibsovo (ivosidenib) is a once-daily oral medication that targets a specific gene mutation called ...
Inqovi
Inqovi (decitabine and cedazuridine) is used for the treatment of myelodysplastic syndromes (MDS) ...
Rytelo
Rytelo (imetelstat) is an injectable telomerase inhibitor that may be used to treat adults with ...
Onureg
Onureg (azacitidine) is used for the continued treatment of adult patients with acute myeloid ...
Ivosidenib
Ivosidenib systemic is used for acute myeloid leukemia, biliary tract tumor, myelodysplastic syndrome
Luspatercept
Luspatercept (brand name Reblozyl) is used to treat anemia (low red blood cells) in certain ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.